American Association for Cancer Research
Browse

Supplementary Table S12 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution

Download (856.78 kB)
dataset
posted on 2024-09-04, 07:41 authored by Iros Barozzi, Neil Slaven, Eleonora Canale, Rui Lopes, Inês Amorim Monteiro Barbosa, Melusine Bleu, Diana Ivanoiu, Claudia Pacini, Emanuela Mensa’, Alfie Chambers, Sara Bravaccini, Sara Ravaioli, Balázs Győrffy, Maria Vittoria Dieci, Giancarlo Pruneri, Giorgio Giacomo Galli, Luca Magnani

Supplementary Table S12: Summary of SNVs and INDELs identified by SIDV. S12.1: full list of SNVs and INDELs. Chromosome and position on the chromosome (hg38 coordinates) are indicated for each variant, along with the reference and detected alternative allele. Also, the table indicates the donor, and whether the variant allele was directly detected in the primary (P_CALL) and/or the metastatic material (M_CALL). S12.2: tumor purity estimation for each sample and site (P = primary; M = metastasis) is listed, along with the size of the subset of SNVs used for the purity estimation analysis. S12.3: final annotation of the SNVs after sample-specific purity correction. For each SNV, genomic coordinates, reference and alternative alleles, donor identifier, and evidence (filtered read counts) supporting the different alleles in normal (N), primary (P) and metastatic (M) samples are provided. For both primary and metastatic samples, the variant allele frequency (VAF), along with the estimated purity for the sample, the estimated copy number alterations of the region bearing the variant (CNA) and the purity-corrected VAF, or cancer-cell fraction (CCF), are indicated. S12.4: regions showing an enrichment in either amplifications (amp) or deletions (del) across the metastatic samples as compared to the matched primary samples, are indicated.

Funding

Cancer Research UK (CRUK)

History

ARTICLE ABSTRACT

Only a handful of somatic alterations have been linked to endocrine therapy resistance in hormone-dependent breast cancer, potentially explaining ∼40% of relapses. If other mechanisms underlie the evolution of hormone-dependent breast cancer under adjuvant therapy is currently unknown. In this work, we employ functional genomics to dissect the contribution of cis-regulatory elements (CRE) to cancer evolution by focusing on 12 megabases of noncoding DNA, including clonal enhancers, gene promoters, and boundaries of topologically associating domains. Parallel epigenetic perturbation (CRISPRi) in vitro reveals context-dependent roles for many of these CREs, with a specific impact on dormancy entrance and endocrine therapy resistance. Profiling of CRE somatic alterations in a unique, longitudinal cohort of patients treated with endocrine therapies identifies a limited set of noncoding changes potentially involved in therapy resistance. Overall, our data uncover how endocrine therapies trigger the emergence of transient features which could ultimately be exploited to hinder the adaptive process.Significance: This study shows that cells adapting to endocrine therapies undergo changes in the usage or regulatory regions. Dormant cells are less vulnerable to regulatory perturbation but gain transient dependencies which can be exploited to decrease the formation of dormant persisters.